Ascendis Pharma A/S' (NASDAQ:ASND) Popularity With Investors Is Under Threat From Overpricing

Simply Wall StDec 24 07:41 ET

Evercore Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $220

Moomoo NewsDec 20 13:31 ET · Ratings

Ascendis Pharma's YORVIPATH Now Commercially Available In The U.S. For The Treatment Of Hypoparathyroidism In Adults

BenzingaDec 19 08:42 ET

Jefferies Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $194

Moomoo NewsDec 18 10:31 ET · Ratings

A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $167 to $211

Moomoo NewsDec 17 08:00 ET · Ratings

Express News | Ascendis Pharma A/S : Jefferies Raises Target Price to $194 From $191

ReutersDec 17 00:11 ET